http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 16:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Geron+Corporation+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26801491.html <p>FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.</p> <p>The stock options have an exercise price of $1.44 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying http://www.streetinsider.com/Press+Releases/Geron+Corporation+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26801491.html Wed, 22 Jul 2026 16:01:00 -0400 GERN O.00178595 http://www.streetinsider.com/Press+Releases/Geron+Corporation+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26801491.html <p>FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.</p> <p>The stock options have an exercise price of $1.44 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying http://www.streetinsider.com/Press+Releases/Geron+Corporation+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26801491.html Wed, 22 Jul 2026 16:01:00 -0400 GERN O.00178595 http://www.streetinsider.com/Globe+Newswire/Geron+Corporation+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26801491.html <p>FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.</p> <p>The stock options have an exercise price of $1.44 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying http://www.streetinsider.com/Globe+Newswire/Geron+Corporation+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26801491.html Wed, 22 Jul 2026 16:01:00 -0400 GERN O.00178595 http://www.streetinsider.com/Globe+Newswire/Geron+Corporation+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26801491.html <p>FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron.</p> <p>The stock options have an exercise price of $1.44 per share, which is equal to the closing price of Geron’s common stock on the grant date, have a ten-year term and vest over four years, with 12.5% of the shares underlying http://www.streetinsider.com/Globe+Newswire/Geron+Corporation+Reports+Inducement+Grants+Under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26801491.html Wed, 22 Jul 2026 16:01:00 -0400 GERN O.00178595 http://www.streetinsider.com/Press+Releases/Geron+Plans+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26798032.html <p>FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cx9O3M1crw_AlNcxONoTUFSIY4D41FSJ1O81cbwh5Mb6X4WNUkAxI3nQKSEyqibeDzjoAxYxdXaLBw38cvnBp2rQJeR6w_XINw-ZvzNXcW0=" rel="nofollow" target="_blank">Investors and Media</a> section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.</p> <p>A live and archived audio webcast of the conference call will be http://www.streetinsider.com/Press+Releases/Geron+Plans+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26798032.html Wed, 22 Jul 2026 07:00:00 -0400 GERN O.00178595 http://www.streetinsider.com/Press+Releases/Geron+Plans+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26798032.html <p>FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cx9O3M1crw_AlNcxONoTUFSIY4D41FSJ1O81cbwh5Mb6X4WNUkAxI3nQKSEyqibeDzjoAxYxdXaLBw38cvnBp2rQJeR6w_XINw-ZvzNXcW0=" rel="nofollow" target="_blank">Investors and Media</a> section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.</p> <p>A live and archived audio webcast of the conference call will be http://www.streetinsider.com/Press+Releases/Geron+Plans+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26798032.html Wed, 22 Jul 2026 07:00:00 -0400 GERN O.00178595 http://www.streetinsider.com/Globe+Newswire/Geron+Plans+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26798032.html <p>FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cx9O3M1crw_AlNcxONoTUFSIY4D41FSJ1O81cbwh5Mb6X4WNUkAxI3nQKSEyqibeDzjoAxYxdXaLBw38cvnBp2rQJeR6w_XINw-ZvzNXcW0=" rel="nofollow" target="_blank">Investors and Media</a> section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.</p> <p>A live and archived audio webcast of the conference call will be http://www.streetinsider.com/Globe+Newswire/Geron+Plans+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26798032.html Wed, 22 Jul 2026 07:00:00 -0400 GERN O.00178595 http://www.streetinsider.com/Globe+Newswire/Geron+Plans+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26798032.html <p>FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the <a target="_blank" href="https://www.globenewswire.com/Tracker?data=cx9O3M1crw_AlNcxONoTUFSIY4D41FSJ1O81cbwh5Mb6X4WNUkAxI3nQKSEyqibeDzjoAxYxdXaLBw38cvnBp2rQJeR6w_XINw-ZvzNXcW0=" rel="nofollow" target="_blank">Investors and Media</a> section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.</p> <p>A live and archived audio webcast of the conference call will be http://www.streetinsider.com/Globe+Newswire/Geron+Plans+to+Announce+Second+Quarter+2026+Financial+Results+on+August+5%2C+2026/26798032.html Wed, 22 Jul 2026 07:00:00 -0400 GERN O.00178595 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Press+Releases/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Globe+Newswire/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Globe+Newswire/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Globe+Newswire/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Globe+Newswire/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639 http://www.streetinsider.com/Globe+Newswire/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html <ul><li><em>The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.</em></li><li style="margin-bottom:8pt;"><em>Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms.</em></li></ul> <p><br/>CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=p9tDFKE1hrjg5Fwq-TkAWNYFCpA6BIcDwHq4kEdcqKoj18m8wT-VqlpykciK0Cr37VcaulSDVCd8GvZL6JfZu9KrnpO0m3Sf3TtHYzvBRS4=" rel="nofollow" target="_blank">Rectify Pharmaceuticals</a>, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the http://www.streetinsider.com/Globe+Newswire/Rectify+Pharmaceuticals+Announces+Appointment+of+Constantine+Chinoporos+as+Executive+Chairman/26771791.html Wed, 15 Jul 2026 09:00:00 -0400 A.02975482 A.31197700 A.40557829 A.50114115 A.50216925 ENGN GERN O.00178595 O.00358218 O.00831659 O.29384338 O.41016837 O.49254168 O.61395639